KR101831229B1 - Ｈｓｐ65-유도 펩티드-6에 특이한 인간화 항체, 그것의 방법 및 용도 - Google Patents

Ｈｓｐ65-유도 펩티드-6에 특이한 인간화 항체, 그것의 방법 및 용도 Download PDF

Info

Publication number
KR101831229B1
KR101831229B1 KR1020127008389A KR20127008389A KR101831229B1 KR 101831229 B1 KR101831229 B1 KR 101831229B1 KR 1020127008389 A KR1020127008389 A KR 1020127008389A KR 20127008389 A KR20127008389 A KR 20127008389A KR 101831229 B1 KR101831229 B1 KR 101831229B1
Authority
KR
South Korea
Prior art keywords
ser
tyr
seq
leu
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127008389A
Other languages
English (en)
Korean (ko)
Other versions
KR20120060224A (ko
Inventor
야콥 나파르스테크
쉬라 야이르
Original Assignee
프로탭 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프로탭 리미티드 filed Critical 프로탭 리미티드
Publication of KR20120060224A publication Critical patent/KR20120060224A/ko
Application granted granted Critical
Publication of KR101831229B1 publication Critical patent/KR101831229B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127008389A 2009-09-06 2010-09-06 Ｈｓｐ65-유도 펩티드-6에 특이한 인간화 항체, 그것의 방법 및 용도 Expired - Fee Related KR101831229B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24021809P 2009-09-06 2009-09-06
US61/240,218 2009-09-06
PCT/IL2010/000731 WO2011027349A1 (en) 2009-09-06 2010-09-06 Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof

Publications (2)

Publication Number Publication Date
KR20120060224A KR20120060224A (ko) 2012-06-11
KR101831229B1 true KR101831229B1 (ko) 2018-02-22

Family

ID=43648941

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127008389A Expired - Fee Related KR101831229B1 (ko) 2009-09-06 2010-09-06 Ｈｓｐ65-유도 펩티드-6에 특이한 인간화 항체, 그것의 방법 및 용도

Country Status (12)

Country Link
US (3) US8680241B2 (enExample)
EP (2) EP3366308A1 (enExample)
JP (1) JP5781514B2 (enExample)
KR (1) KR101831229B1 (enExample)
CN (1) CN102740877B (enExample)
AU (1) AU2010290844B2 (enExample)
BR (1) BR112012004983A2 (enExample)
CA (1) CA2772567A1 (enExample)
IN (1) IN2012DN02869A (enExample)
MX (1) MX2012002768A (enExample)
RU (1) RU2596925C2 (enExample)
WO (1) WO2011027349A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
BR112017005451A2 (pt) * 2014-10-24 2018-01-02 Hoffmann La Roche anticorpo humanizado e métodos para a seleção de um ou mais fragmentos fv de anticorpo variantes e para a produção de um anticorpo
EP3247382B1 (en) 2015-01-22 2020-05-06 Ram, Isanaka Peptide for treating inflammatory diseases
WO2017005923A1 (en) * 2015-07-09 2017-01-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lentiviral vector expressing membrane-anchored or secreted antibody
MX385370B (es) * 2016-03-31 2025-03-18 Immutrix Therapeutics Inc Metodo para el tratamiento extracorporeo de preeclampsia y trastornos relacionados.
US11987631B2 (en) * 2018-08-01 2024-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-BTN3A antibodies and their use in treating cancer or infectious disorders
WO2025155809A2 (en) * 2024-01-18 2025-07-24 Nextcure, Inc. Compositions and methods for modulating vstm-1 mediated signal transduction
WO2025231127A1 (en) * 2024-05-02 2025-11-06 The Regents Of The University Of California Compositions and methods for intracellular antigen targeting with antibodies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123535A1 (en) * 1998-11-05 2005-06-09 Hadasit Medical Research Services & Development Ltd. Novel amino acid sequences, DNA encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
DE69929454T2 (de) * 1998-11-05 2006-09-28 Hadasit Medical Research Services & Development Co. Ltd. Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen
WO2003057527A2 (en) * 2001-12-31 2003-07-17 L.A.S. Trust, Ein 02/6105365 Recreational vehicle
EP1619521A1 (en) 2004-07-22 2006-01-25 IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. Capacitive transmitter electrode
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
CN101115771B (zh) 2005-02-03 2013-06-05 安迪拓普有限公司 人类抗体和蛋白质
WO2007024921A2 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
KR101361887B1 (ko) 2006-03-02 2014-02-21 안티토페 리미티드 Ｔ 세포 검사
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
CA2705292C (en) * 2007-11-13 2016-06-21 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against tl1a
RU2011143776A (ru) 2009-03-30 2013-05-10 Протаб Лтд. Белок, ассоциированный с аденилатциклазой (сар1) и применение его в качестве мишени для иммуномодуляции
US20140170157A1 (en) * 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123535A1 (en) * 1998-11-05 2005-06-09 Hadasit Medical Research Services & Development Ltd. Novel amino acid sequences, DNA encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Autoimmunity Reviews. Vol. 3, No. 7-8, pp. 588-589 (2004)

Also Published As

Publication number Publication date
AU2010290844A1 (en) 2012-03-15
CN102740877B (zh) 2015-01-14
IN2012DN02869A (enExample) 2015-07-24
EP3366308A1 (en) 2018-08-29
EP2475383A4 (en) 2013-07-17
US8680241B2 (en) 2014-03-25
WO2011027349A1 (en) 2011-03-10
RU2596925C2 (ru) 2016-09-10
JP5781514B2 (ja) 2015-09-24
CA2772567A1 (en) 2011-03-10
KR20120060224A (ko) 2012-06-11
AU2010290844B2 (en) 2015-04-09
RU2012106891A (ru) 2013-10-27
US20120156201A1 (en) 2012-06-21
US20140170138A1 (en) 2014-06-19
US20170218056A1 (en) 2017-08-03
MX2012002768A (es) 2012-06-28
JP2013503852A (ja) 2013-02-04
CN102740877A (zh) 2012-10-17
BR112012004983A2 (pt) 2021-02-23
EP2475383A1 (en) 2012-07-18

Similar Documents

Publication Publication Date Title
KR101831229B1 (ko) Ｈｓｐ65-유도 펩티드-6에 특이한 인간화 항체, 그것의 방법 및 용도
KR101809441B1 (ko) 특이적 결합 단백질 및 이의 용도
TWI820377B (zh) 抗ｏｘ４０抗體及其使用方法
JP6502959B2 (ja) Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用
CN109414455B (zh) Bcma结合分子及其使用方法
AU701578B2 (en) Immunoglobulins devoid of light chains
CN110248674B (zh) 针对vegf的合成抗体及其用途
RS52690B (sr) Humana anti-ifn-gama neutrališuća antitela kao selektivni inhibitori ifn-gama puta
JP2022545117A (ja) 抗ｐｄ－ｌ１シングルドメイン抗体
TW200930728A (en) Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
JP2020520667A (ja) 免疫関連障害のための抗体−サイトカイングラフト化タンパク質及び使用方法
US20020141990A1 (en) Anti-RSV human monoclonal antibodies
EP3615569A1 (en) Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP0977590A1 (en) Human monoclonal antibodies
CN101896502B (zh) 抗人TNFα单抗、分子进化及其应用
KR20070022045A (ko) 장애의 치료

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210215

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210215